Literature DB >> 23147768

Chronic kidney disease: Safe anticoagulation for patients with CKD--are we there yet?

Elsayed Z Soliman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23147768     DOI： 10.1038/nrneph.2012.244

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  9 in total

1.  Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Usman Baber; Virginia J Howard; Jonathan L Halperin; Elsayed Z Soliman; Xiao Zhang; William McClellan; David G Warnock; Paul Muntner
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-11-13

2.  Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John J You; Daniel E Singer; Patricia A Howard; Deirdre A Lane; Mark H Eckman; Margaret C Fang; Elaine M Hylek; Sam Schulman; Alan S Go; Michael Hughes; Frederick A Spencer; Warren J Manning; Jonathan L Halperin; Gregory Y H Lip
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Alvaro Alonso; Faye L Lopez; Kunihiro Matsushita; Laura R Loehr; Sunil K Agarwal; Lin Y Chen; Elsayed Z Soliman; Brad C Astor; Josef Coresh
Journal:  Circulation       Date:  2011-06-06       Impact factor: 29.690

Review 4.  Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk.

Authors:  Ricarda Marinigh; Deirdre A Lane; Gregory Y H Lip
Journal:  J Am Coll Cardiol       Date:  2011-03-22       Impact factor: 24.094

5.  Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.

Authors:  Stefan H Hohnloser; Ziad Hijazi; Laine Thomas; John H Alexander; John Amerena; Michael Hanna; Matyas Keltai; Fernando Lanas; Renato D Lopes; Jose Lopez-Sendon; Christopher B Granger; Lars Wallentin
Journal:  Eur Heart J       Date:  2012-08-29       Impact factor: 29.983

6.  Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC).

Authors:  Elsayed Z Soliman; Ronald J Prineas; Alan S Go; Dawei Xie; James P Lash; Mahboob Rahman; Akinlolu Ojo; Val L Teal; Nancy G Jensvold; Nancy L Robinson; Daniel L Dries; Lydia Bazzano; Emile R Mohler; Jackson T Wright; Harold I Feldman
Journal:  Am Heart J       Date:  2010-06       Impact factor: 4.749

7.  Quality of care for atrial fibrillation among patients hospitalized for heart failure.

Authors:  Jonathan P Piccini; Adrian F Hernandez; Xin Zhao; Manesh R Patel; William R Lewis; Eric D Peterson; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2009-09-29       Impact factor: 24.094

Review 8.  Dilemmas in the management of atrial fibrillation in chronic kidney disease.

Authors:  Holger Reinecke; Eva Brand; Rolf Mesters; Wolf-Rüdiger Schäbitz; Marc Fisher; Hermann Pavenstädt; Günter Breithardt
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

9.  Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.

Authors:  Alan S Go; Margaret C Fang; Natalia Udaltsova; Yuchiao Chang; Niela K Pomernacki; Leila Borowsky; Daniel E Singer
Journal:  Circulation       Date:  2009-03-02       Impact factor: 29.690
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.